Why I’m reconsidering Mansa X after testing Arvocap’s Multi-Asset Fund

Arvocap has done it again. Last year, I decided to put some money into Arvocap—not as a major allocation, but simply to test the waters. After researching the firm and reviewing their product lineup, I settled on the Arvocap Multi-Asset Strategy Special Fund, which is broadly comparable to products like Mansa X and Oak Special Fund in terms of mandate and risk profile. At the beginning, the returns were… underwhelming. Like most multi-asset strategies, performance early on required patience. The fund moved slowly at first, and there were moments where it felt like one of those investments that quietly tests your conviction before it rewards it. Nothing alarming—but nothing exciting either. Then things changed. As the year progressed, the fund’s performance began to accelerate, and by the end of 2025, the numbers told a very different story. The Arvocap Multi-Asset Strategy Special Fund delivered a net return of 36.86% for the year, after all fees. To put that into context, this wasn’t just positive performance—it was well above its benchmark, which stood at 7.23% for the same period. What stood out to me wasn’t just the headline return, but the consistency and structure behind it. The fund benefited from diversified exposure across asset classes while still capturing upside during favorable market conditions. In other words, it behaved exactly the way a well-run multi-asset fund is supposed to. This naturally led me to reassess something I hadn’t questioned in a while: Does it still make sense to keep capital in Mansa X? Mansa X, like Oak Special Fund, has been a popular option for investors looking for an alternative to traditional money market or fixed income products. But when you compare recent outcomes, Arvocap’s Multi-Asset Fund presents a compelling case. With stronger risk-adjusted returns, transparent reporting, and performance that materially outpaced its benchmark in 2025, it arguably offers better capital efficiency for investors willing to tolerate modest volatility. That doesn’t mean Mansa X is a bad product. It simply means that markets evolve—and so should capital allocation decisions. What worked well in one cycle may no longer be optimal in the next. For me, testing Arvocap wasn’t about chasing returns. It was about validating whether the strategy, execution, and risk management could deliver over time. After seeing how the fund performed in 2025, I’m increasingly convinced that reallocating part of my portfolio away from Mansa X and into Arvocap’s Multi-Asset Strategy may be the more logical move going forward. Sometimes, the smartest investment decision isn’t finding something new—it’s having the data to confidently change your mind. For me to do this, I will need a gradual pull towards Arvocap, nothing drastic; we are still testing. Arvocap is new in the market, so yes, we are cautious, but overall, what started for me as a simple test ended up proving that some newcomers can make a big change in your investment portfolio.